FAIRFIELD, N.J., Dec. 23 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. today announced that the Company’s Doak Dermatologics subsidiary has introduced five new prescription-only line extensions during September 2005 and the Fourth Quarter 2005. Keralac(TM) NAILSTIK (50% urea) and Keralac(TM) OINTMENT (50% urea) have been added to the Keralac(TM) line of Urea-based keratolytics; ADOXA(R) Pak(TM) 1/75mg, a new convenient pack, and ADOXA(R) Pak(TM) 1/150mg, the newest strength of ADOXA(R) (doxycycline tablets), an antibiotic used primarily as an adjunctive treatment for severe acne, have been added to the ADOXA(R) line; and ZODERM(R) REDI- PADS(TM) (benzoyl peroxide), a line extension to the ZODERM(R) family of anti- acne therapies, has been added. These line extensions have been launched as part of Bradley’s brand life cycle management strategy and aim to minimize the effects of generic competition.
Keralac(TM) NAILSTIK offers an innovative and easy-to-use applicator to deliver a 50% urea therapy for the treatment of diseased and damaged nails and Keralac(TM) OINTMENT provides a targeted, site-specific keratolytic therapy. Generic versions of Keralac(TM) Nail Gel (50% urea), Lotion (35% urea) and Cream (50% urea) were introduced during January 2005, January 2005 and July 2005, respectively. Bradley’s marketing efforts for Keralac(TM) NAILSTIK and Keralac(TM) OINTMENT are ongoing.
In addition to the ADOXA(R) family’s new ADOXA(R) Pak(TM) 1/75mg strength, the ADOXA(R) Pak(TM) 1/150mg is the first and only 150 mg doxycycline monohydrate scored tablet that provides the physician with dosing flexibility. The easy-to-take, easy-to-remember Pak offers the additional advantage of promoting patient compliance. Generic versions of ADOXA(R) 50mg and 100mg loose tablets in bottles, including Bradley’s authorized generic versions of ADOXA(R) 50mg and 100mg loose tablets in bottles, were launched during December 2005. Bradley’s marketing efforts for ADOXA(R) Pak(TM) 1/150mg strength and 75mg and 100mg Paks are ongoing.
ZODERM(R), the moisturizing benzoyl peroxide, is now available as ZODERM(R) REDI-PADS(TM), the first and only benzoyl peroxide cleanser in a pad available in 4.5%, 6.5% and 8.5% strengths of benzoyl peroxide in a 10% urea vehicle. A generic version of ZODERM(R) was launched during July 2005. Bradley’s marketing efforts for ZODERM(R) REDI-PADS(TM) are ongoing.
President and CEO, Daniel Glassman, stated, “Each of these new line extensions builds on successful brands Bradley has brought to market in the past by offering convenient, beneficial delivery systems that can enhance patient compliance and simplify physician prescribing. The addition of these line extensions reflects Bradley’s commitment to life cycle management.”
ADOXA(R) Tablets are contraindicated in persons who have shown any sensitivity to any of the tetracyclines. The use of drugs of the tetracycline class during tooth development (last half of pregnancy, infancy, and childhood to 8 years) may cause permanent discoloration of the teeth (yellow-gray- brown). Photosensitivity manifested by exaggerated sunburn has been observed in some individuals taking tetracyclines. Treatment should be discontinued at first evidence of skin erythema. Concurrent use of tetracycline may render oral contraceptives less effective. Please see full Prescribing Information at http://www.bradpharm.com.
Keralac(TM) NAILSTIK is for external use only. Avoid contact with eyes, lips or mucous membranes. If redness or irritation occurs, discontinue use. Please see full Prescribing Information at http://www.bradpharm.com.
Keralac(TM) OINTMENT is for external use only. Avoid contact with eyes, lips or mucous membranes. If redness or irritation occurs, discontinue use. Please see full Prescribing Information at http://www.bradpharm.com.
ZODERM(R) REDI-PADS(TM) are for external use only. Contact with eyes, lips or mucous membranes should be avoided. If severe irritation develops, use should be discontinued. Patients should be advised to avoid unnecessary sun exposure while using ZODERM(R) REDI-PADS(TM). Please see full Prescribing Information at http://www.bradpharm.com.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements that address activities, events or developments that Bradley expects, believes or anticipates will or may occur in the future, such as earnings estimates, other predictions of financial performance, launches by Bradley of new products and market acceptance of Bradley’s products. Forward-looking statements are based on Bradley’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond Bradley’s control. These risks and uncertainties include Bradley’s ability to comply with the restrictive covenants under its credit facility; ability to access the capital markets on attractive terms or at all; ability to favorably resolve the pending SEC informal inquiry and file required financial statements with the SEC, maintain sales of its products, successfully acquire, develop, integrate, or sell new products or effectively react to other risks and uncertainties described from time to time in Bradley’s SEC filings, such as fluctuation of quarterly financial results, estimation of product returns, chargebacks, rebates and allowances, concentration of customers, reliance on third party manufacturers and suppliers, litigation or other proceedings (including the pending class action lawsuits), government regulation and stock price volatility. Further, Bradley cannot accurately predict the impact on its business of the approval, introduction, or expansion by competitors of generic or therapeutically equivalent or comparable versions of Bradley’s products or of any other competing products. In addition, actual results may differ materially from those projected. Bradley undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and 38 international markets. Bradley’s success is based on the strategy of Acquire, Enhance and Grow. Bradley Acquires non-strategic brands, Enhances these brands with line extensions and improved formulations and Grows the products through promotion, advertising and selling activities to optimize life cycle management. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in topical therapies for dermatology and podiatry, and Kenwood Therapeutics, providing gastroenterology, respiratory and other internal medicine brands.
Important announcement:
Daniel Glassman will present at the Raymond James & Associates 27th Annual Institutional Investors Conference, Hyatt Regency Grand Cypress in Orlando, FL, March 5-8th, 2006.
Daniel Glassman will present at the Banc of America Securities LLC, Health Care Conference 2006, to be held at The Four Seasons Hotel in Las Vegas, NV, May 16-18th, 2006.
Please visit Bradley Pharmaceuticals web site at: http://www.bradpharm.com.
Bradley Pharmaceuticals common stock is listed on the NYSE under the symbol BDY.
Bradley Pharmaceuticals, Inc.
CONTACT: Anthony Griffo, Investor Relations of Bradley Pharmaceuticals,Inc., +1-973-882-1505, ext. 313
Web site: http://www.bradpharm.com//